TLDR:
- VolitionRx (VNRX) Stock Rises with First Sale of Nu.Q Cancer Assays in Europe
- VNRX Surges After Securing First Sale of Nu.Q Cancer Assay to European Hospital
- VolitionRx (VNRX) Achieves Milestone with First Sale of Nu.Q Cancer Test in France
- VNRX Stock Climbs on Major Sale of Nu.Q Cancer Assay to Hospices Civils de Lyon
- VolitionRx (VNRX) Advances Cancer Diagnostics with First Commercial Sale in Europe
VolitionRx Limited (VNRX) has made significant progress in the commercialization of its Nu.Q® Cancer assays with a key sale to Hospices Civils de Lyon in France. The sale marks the first commercial order of the assay, representing a critical step in the move from research to clinical use. As a result, the stock surged by over 6% in early trading, reaching a price of $0.31.
Nu.Q Cancer Assays Move Toward Clinical Use
VolitionRx’s Nu.Q Cancer assays are designed to help diagnose cancer and predict outcomes, particularly for non-small cell lung cancer (NSCLC). This sale, made on November 25, 2025, to the prestigious Hospices Civils de Lyon, initiates the internal clinical certification process. The goal is to eventually introduce the test into routine clinical practice for cancer management.
The assays use methylated nucleosome biomarkers to correlate with patient survival and progression-free survival. This provides valuable information on patients’ responses to treatment and identifies those who could benefit from curative care. The sale is a crucial commercial milestone for VolitionRx, moving the Nu.Q assay closer to being a regular part of cancer diagnostic workflows.
Hospices Civils de Lyon will now use the assays for internal verification before deploying them in clinical practice. The hospital’s expertise and high standards in cancer care will ensure that the assay meets rigorous clinical standards. The outcome of this certification process could pave the way for widespread use in cancer care across Europe.
Milestone for Commercial Licensing and Expansion
The successful sale to Hospices Civils de Lyon also represents a significant step toward broader commercial licensing and expansion of Nu.Q Cancer assays. VolitionRx executives have expressed optimism that this sale will trigger additional orders from other institutions. This development positions the company for further growth in the rapidly expanding cancer diagnostics market.
VolitionRx’s CEO, Dr. Andrew Retter, highlighted the role of Nu.Q Cancer in enhancing precision treatment decisions. By improving prognostication and monitoring throughout the treatment journey, the assays provide critical insights to clinicians. This supports the broader goal of improving cancer care and patient outcomes globally.
The commercial success of Nu.Q Cancer is expected to contribute to VolitionRx’s continued market penetration and financial growth. As the company progresses through clinical certification and adoption, it is well-positioned to expand its presence in the diagnostics space. This commercial achievement is a pivotal moment in VolitionRx’s strategy to scale its innovative products.
VolitionRx’s sale of Nu.Q Cancer assays to Hospices Civils de Lyon is a key milestone in the company’s push toward clinical adoption. This first sale sets the stage for broader commercialization and potential licensing agreements with other cancer centers. As the clinical validation process moves forward, VolitionRx continues to make strides in transforming cancer diagnostics and improving patient care outcomes.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
